DaVita Inc. (NYSE:DVA) Sees Large Drop in Short Interest

DaVita Inc. (NYSE:DVA) was the target of a large decrease in short interest in January. As of January 15th, there was short interest totaling 6,943,051 shares, a decrease of 14.2% from the December 31st total of 8,092,541 shares. Based on an average daily volume of 975,529 shares, the days-to-cover ratio is presently 7.1 days. Currently, 10.0% of the company’s stock are short sold. Currently, 10.0% of the company’s stock are short sold. Based on an average daily volume of 975,529 shares, the days-to-cover ratio is presently 7.1 days.

DaVita Price Performance

DaVita stock opened at $141.74 on Thursday. The company has a market cap of $10.01 billion, a price-to-earnings ratio of 14.30, a P/E/G ratio of 0.75 and a beta of 0.99. The firm has a 50-day moving average of $114.12 and a 200-day moving average of $124.94. DaVita has a one year low of $101.00 and a one year high of $178.47.

DaVita (NYSE:DVA) last released its earnings results on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.24 by $0.16. The business had revenue of $3.62 billion for the quarter, compared to analyst estimates of $3.51 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.DaVita’s revenue was up 9.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.24 earnings per share. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, sell-side analysts expect that DaVita will post 10.76 earnings per share for the current year.

Key Stories Impacting DaVita

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: Q4 results beat and margins expanded — DaVita reported Q4 EPS and revenue above consensus, with margin expansion and double‑digit full‑year adjusted EPS growth; the beat and improved profitability are the primary catalyst for the rally. DaVita Stock Up Following Q4 Earnings & Revenue Beat, Margins Expand
• Positive Sentiment: Strong guidance and beat on the quarter — management set FY‑2026 EPS guidance (roughly $13.60–$15.00) and Q1/Q4 results topped analyst estimates (Q4 EPS beat ~$0.16), giving investors clearer forward visibility. This underpins the stock’s move higher. Why Is DaVita (DVA) Stock Rocketing Higher Today
• Positive Sentiment: Home‑health / care expansion via Elara Caring backing — Ares’ PE backing of Elara Caring with participation from DaVita signals continued strategic expansion into home‑based care services, which could broaden DaVita’s addressable market beyond in‑center dialysis. Elara Caring Backed By Ares’ Private Equity Group, Kidney Care Provider DaVita
• Neutral Sentiment: Analyst views mixed — some outlets highlight differing analyst takes on valuation and peers, so while results were strong, consensus sentiment is not uniformly bullish. Monitor revisions from sell‑side firms. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (BSX) and DaVita (DVA)
• Neutral Sentiment: Industry / screen mentions — coverage pieces placing DaVita in broader Dow Jones healthcare or “Buffett‑style” stock lists raise visibility but do not directly change fundamentals. Explore DaVita Within Dow Jones Industrial Average Healthcare Space 3 Warren Buffett-Style Stocks for a Golden Retirement
• Negative Sentiment: Volatility and caution remain — some analyst commentary and independent pieces warn that DVA is still subject to operational and regulatory volatility; investors should expect trading swings despite current strength. DaVita: Some Success Is Possible, But Volatility Is Still Heavy
• Negative Sentiment: High intraday volume and large after‑hours moves increase short‑term risk — big gaps and elevated volume can amplify reversals; traders should watch liquidity and news flow. Stocks making the biggest moves after hours: Palantir, NXP Semiconductors, DaVita and more

Hedge Funds Weigh In On DaVita

A number of institutional investors have recently added to or reduced their stakes in the company. Versor Investments LP lifted its stake in DaVita by 32.3% in the fourth quarter. Versor Investments LP now owns 4,497 shares of the company’s stock valued at $511,000 after acquiring an additional 1,097 shares during the last quarter. Denali Advisors LLC bought a new stake in shares of DaVita in the 4th quarter valued at about $481,000. Ethic Inc. lifted its stake in DaVita by 9.2% in the 4th quarter. Ethic Inc. now owns 2,723 shares of the company’s stock valued at $309,000 after purchasing an additional 229 shares during the last quarter. Sequoia Financial Advisors LLC grew its holdings in DaVita by 62.1% during the fourth quarter. Sequoia Financial Advisors LLC now owns 3,313 shares of the company’s stock worth $376,000 after purchasing an additional 1,269 shares during the period. Finally, Acorn Financial Advisory Services Inc. ADV increased its position in DaVita by 10.5% during the fourth quarter. Acorn Financial Advisory Services Inc. ADV now owns 2,230 shares of the company’s stock worth $253,000 after buying an additional 212 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on DVA shares. Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a report on Monday, December 29th. UBS Group upped their target price on shares of DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research note on Wednesday. Wall Street Zen cut DaVita from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Barclays boosted their price target on DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a report on Tuesday. Finally, Truist Financial decreased their price objective on DaVita from $140.00 to $128.00 and set a “hold” rating for the company in a report on Monday, January 5th. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $155.50.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.